| Identification | Back Directory | [Name]
CC220 | [CAS]
1323403-33-3 | [Synonyms]
CC220
CS-2470
Iberdomide
Iberdomide(CC220)
CC-220 Iberdomide
CC220; CC 220; CC-220
(S)-3-[4-(4-morpholin-4-yl-methyl-benzyloxy)-1-oxo-1,3-dihydro-isoindol-2-yl]-piperidine-2,6-dione
2,6-Piperidinedione, 3-[1,3-dihydro-4-[[4-(4-morpholinylmethyl)phenyl]methoxy]-1-oxo-2H-isoindol-2-yl]-, (3S)- | [Molecular Formula]
C25H27N3O5 | [MDL Number]
MFCD31382133 | [MOL File]
1323403-33-3.mol | [Molecular Weight]
449.5 |
| Chemical Properties | Back Directory | [Boiling point ]
717.8±60.0 °C(Predicted) | [density ]
1.332±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:125.0(Max Conc. mg/mL);278.09(Max Conc. mM) | [form ]
A crystalline solid | [pka]
10.70±0.40(Predicted) | [color ]
White to off-white | [InChIKey]
IXZOHGPZAQLIBH-NRFANRHFSA-N | [SMILES]
N1C(=O)CC[C@H](N2CC3=C(C2=O)C=CC=C3OCC2=CC=C(CN3CCOCC3)C=C2)C1=O |
| Hazard Information | Back Directory | [Uses]
Iberdomide (CC-220) is an orally active and potent cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC50 of ~150?nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities[1][2]. | [in vivo]
Iberdomide (CC-220; 10 mg/kg; oral gavage) after 6 or 24 hours causes higher hCRBN expression in hC343 splenocytes correlated to deeper IKZF1/3 downregulation in WT (C57BL/6), hC123, or-343, (representing two different transgenic founder lines expressing hCRBN) and mCrbn-/- mice[2].
| [IC 50]
Cereblon | [storage]
Store at -20°C | [References]
[1] Chad C Bjorklund, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020 Apr;34(4):1197-1201. DOI:10.1038/s41375-019-0620-8
[2] Erin W Meermeier, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021 Jul;2(4):354-369. DOI:10.1158/2643-3230.BCD-21-0038 |
|
|